|
186 Products |
| 186 Products |
|
1696 Diseases |  |
95004 News |  |
| «12...212213214215216217218219220221222...10661067» |
- || methylphenidate tablet / Generic mfg., dexamethasone / Generic mfg.
Review, Journal, Metastases: Management of Fatigue in Patients with Advanced Cancer. (Pubmed Central) - Jan 20, 2023
The authors advise considering the use of psycho-educational approaches or CBT in those patients who are able to engage in such forms of therapy. In patients near the end-of-life, the authors advise use of dexamethasone (short-term use) and other pharmacological treatments only on the basis of a clinical trial.
- || triamcinolone acetonide / Generic mfg.
Review, Journal: Intralesional corticosteroid administration in the treatment of keloids: a scoping review on injection methods. (Pubmed Central) - Jan 20, 2023
Triamcinolone acetonide was used in 37 (97.4%) studies...Key messages There is incomplete reporting and substantial heterogeneity in many aspects of ICA and study design among RCTs. This scoping review underscores the urgent need for standardization of treatment protocol and study design to enhance and uniform research conduct among keloid studies.
- | Decadron (dexamethasone) / Merck (MSD)
Trial completion date, Trial primary completion date: Oral Statins and Protection From Hearing Loss (clinicaltrials.gov) - Jan 20, 2023
P4, N=100, Not yet recruiting, Sponsor: Northwestern University
This scoping review underscores the urgent need for standardization of treatment protocol and study design to enhance and uniform research conduct among keloid studies. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
- | dexamethasone / Generic mfg.
New P4 trial: Dexamethasone vs Ondansetron After Cesarean Delivery (clinicaltrials.gov) - Jan 20, 2023
P4, N=100, Not yet recruiting, Sponsor: Beth Israel Deaconess Medical Center
- | iberdomide (CC-220) / BMS
Enrollment open, Minimal residual disease: COMMANDER: COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (clinicaltrials.gov) - Jan 20, 2023
P1/2, N=80, Recruiting, Sponsor: University of Alabama at Birmingham
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Oct 2024 Not yet recruiting --> Recruiting
- || HR20013 / Jiangsu Hengrui Pharma
Trial completion: Study of HR20013 for Injection in Patients With Malignant Solid Tumors (clinicaltrials.gov) - Jan 20, 2023
P1, N=24, Completed, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| budesonide / Generic mfg.
Clinical: ➡️ Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial,which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy https://t.co/QQYE0mZSSr @IgAN_JBarratt @BradRovin (Twitter) - Jan 19, 2023
- | triamcinolone acetonide / Generic mfg.
Trial completion: Effect of Ultrasound-guided Corticosteroid Injection Versus Palpation-guided Injection for de Quervain's Disease (clinicaltrials.gov) - Jan 19, 2023
P=N/A, N=49, Completed, Sponsor: Shin Kong Wu Ho-Su Memorial Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| dexamethasone / Generic mfg.
Clinical: Where you should focus: 1. that we don't have to speculate, we have data 2. that the suggestion that only those on dexamethasone are true hospitalizations is obviously incomplete given some are hospitalized due to clots, etc. 🧵 (Twitter) - Jan 19, 2023
- | dexamethasone injection / Generic mfg.
Journal: Punicalagin attenuated allergic airway inflammation via regulating IL4/IL-4Rα/STAT6 and Notch- GATA3 pathways. (Pubmed Central) - Jan 19, 2023
The data obtained illustrate the potency of punicalagin as an anti-asthmatic drug. Conclusively, the study's observations suggest the potential therapeutic efficiency of punicalagin in allergic asthma.
- || dexamethasone / Generic mfg.
Review, Journal, Combination therapy: The effectiveness of dexamethasone as a combination therapy for COVID-19. (Pubmed Central) - Jan 19, 2023
Although variable efficacy of other combination therapies has been reported for treating COVID-19 associated with acute respiratory distress syndrome (ARDS), dexamethasone is an extensively used drug in many treatment regimens against COVID-19. The current review aims to explore the role of dexamethasone as an efficient combination treatment for COVID-19.
- | Ryaltris (olopatadine/mometasone) / Glenmark
Journal: Olopatadine/mometasone (Ryaltris) for allergic rhinitis. (Pubmed Central) - Jan 19, 2023
The current review aims to explore the role of dexamethasone as an efficient combination treatment for COVID-19. No abstract available
- | dexamethasone / Generic mfg., dexamethasone injection / Generic mfg.
Trial completion date, Trial primary completion date, HEOR, Head-to-Head: The Effects of IV vs Oral Dexamethasone on Postoperative Nausea, Vomiting, and Pain (clinicaltrials.gov) - Jan 19, 2023
P4, N=126, Recruiting, Sponsor: University of Colorado, Denver
No abstract available Trial completion date: Oct 2021 --> May 2023 | Trial primary completion date: Oct 2021 --> May 2023
- | Sarclisa (isatuximab-irfc) / Sanofi
New P2 trial, Minimal residual disease, Post-transplantation: EMAT: Elimination of Minimal Residual Disease After Transplant (clinicaltrials.gov) - Jan 19, 2023
P2, N=31, Not yet recruiting, Sponsor: Medical College of Wisconsin
- | methylprednisolone sodium succinate / Generic mfg.
Trial completion: Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY) (clinicaltrials.gov) - Jan 19, 2023
P3, N=76, Completed, Sponsor: University Children's Hospital Basel
Trial completion date: Oct 2021 --> May 2023 | Trial primary completion date: Oct 2021 --> May 2023 Active, not recruiting --> Completed
- || Darzalex (daratumumab) / J&J
Clinical, Review, Journal, IO biomarker: Diagnosis and Treatment of AL Amyloidosis. (Pubmed Central) - Jan 19, 2023
Many relapsed/refractory patients are also treated with daratumumab combination, but novel regimens will be needed to rescue daratumumab-exposed subjects. Immunomodulatory drugs are the current cornerstone of rescue therapy, while immunotherapy targeting B-cell maturation antigen and inhibitors of Bcl-2 are promising alternatives.
- || dexamethasone / Generic mfg.
Pretty sure dexamethasone was being used during at least some of the study period (Twitter) - Jan 19, 2023
- ||| Clinical: Also —- very important to note — this is in patients infected before vaccinations, Paxlovid, baricitinib, actemra, monoclonale, dexamethasone etc etc. (Twitter) - Jan 19, 2023
- | Journal: Formation of polychlorinated dibenzo-p-dioxins and furans (PCDD/Fs) in the electrochemical oxidation of polluted waters with pharmaceuticals used against COVID-19. (Pubmed Central) - Jan 18, 2023
The maximum measured concentration of PCDD/Fs was around 2700 pg L for the amoxicillin case in NaCl medium. The obtained results emphasize the importance of not underestimating the potential formation of these highly toxic trace by-products, in addition to the correct selection of oxidation processes and operation variables, in order to avoid final higher toxicity in the medium.
- | cyclophosphamide / Generic mfg., methylprednisolone sodium succinate / Generic mfg., azathioprine / Generic mfg.
Journal: Clinicohistological Profile and Outcomes of Rapidly Progressive Glomerulonephritis: A Prospective Study from North India. (Pubmed Central) - Jan 18, 2023
Pauci-immune RPGN is the most common cause of RPGN followed by immune-complex and anti-GBM disease. Entry serum creatinine, eGFR, and RRT on admission predicted the outcome.
- | Akeega (abiraterone/niraparib) / J&J, Zejula (niraparib) / GSK, J&J
New P2 trial, Metastases: CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations (clinicaltrials.gov) - Jan 18, 2023
P2, N=30, Not yet recruiting, Sponsor: Mayo Clinic
- | dexamethasone / Generic mfg.
New P1 trial: The Analgesic Efficacy of Two Bupivacaine Concentrations for Combined Ilioinguinal and Iliohypogastric Nerve Block in Postherniorrhaphy Pain (clinicaltrials.gov) - Jan 18, 2023
P1, N=90, Not yet recruiting, Sponsor: Tanta University
- || avadomide (CC-122) / BMS
New P1 trial: A Rollover Study of CC-122 (clinicaltrials.gov) - Jan 18, 2023
P1, N=12, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- ||| fluticasone propionate controlled release (EP-104) / Eupraxia Pharma
Enrollment closed: Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee (clinicaltrials.gov) - Jan 18, 2023
P2, N=318, Active, not recruiting, Sponsor: Eupraxia Pharmaceuticals Inc.
Entry serum creatinine, eGFR, and RRT on admission predicted the outcome. Recruiting --> Active, not recruiting
- | Sarclisa (isatuximab-irfc) / Sanofi
Enrollment closed: GMMG-CONCEPT: Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone (clinicaltrials.gov) - Jan 18, 2023
P2, N=246, Active, not recruiting, Sponsor: Universit
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | triamcinolone acetonide / Generic mfg.
Trial completion, Enrollment change, Trial completion date: Knee Steroid Injection and Blood Sugar Signatur (clinicaltrials.gov) - Jan 18, 2023
P=N/A, N=11, Completed, Sponsor: University of Texas Southwestern Medical Center
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed | N=45 --> 11 | Trial completion date: Nov 2023 --> Nov 2022
- Ventolin (albuterol) / GSK
Trial completion: An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients (clinicaltrials.gov) - Jan 18, 2023
P4, N=40, Completed, Sponsor: AstraZeneca
Enrolling by invitation --> Completed | N=45 --> 11 | Trial completion date: Nov 2023 --> Nov 2022 Active, not recruiting --> Completed
- || Review, Journal: Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments. (Pubmed Central) - Jan 18, 2023
As regards non-CAR-T treatments, the ranking in OS was headed by isatuximab plus dexamethasone, followed by belantamab, selinexor, and melflufen plus dexamethasone. In conclusion, while the Shiny method has confirmed its validity in reconstructing individual patient data, our indirect comparisons have offered some original clues to interpret the results of OS published in these studies.
- | dexamethasone / Generic mfg.
Observational data, Journal: A hyperinflammation clinical risk tool, HI5-NEWS2, stratifies hospitalised COVID-19 patients to associate risk of death and effect of early dexamethasone in an observational cohort. (Pubmed Central) - Jan 18, 2023
Therefore, the HI5-NEWS2 score could be utilised to stratify randomised clinical trials to test whether intensified anti-inflammatory therapy would further benefit high risk patients and whether alternative approaches would benefit low risk groups. Considering its recognised morbidity, we suggest that early dexamethasone should not be routinely prescribed for HI5-NEWS2 low risk individuals with COVID-19 and clinicians should cautiously assess the risk benefit of this intervention in all cases.
- |||| Oncocort (pegylated liposomal dexamethasone) / Enceladus
Clinical, PK/PD data: Liposomal Dexamethasone - I never would have imagined but long acting dose can certainly have value for our patients taking 100's pills. Phase I study to investigate pharmacokinetics and safety of liposomal dexamethasone in patients with MM https://t.co/Qd1F5ZICNC #mmsm (Twitter) - Jan 17, 2023
- | cabazitaxel / Generic mfg.
Journal: Development of a Plasmonic Sensor for a Chemotherapeutic Agent Cabazitaxel. (Pubmed Central) - Jan 17, 2023
As a result of the adsorption studies, the limit of detection and limit of quantitation values were found to be 0.012 and 0.036 μg/mL, respectively. High-performance liquid chromatography analysis was used to validate the response of the cabazitaxel-imprinted sensor.
- | Journal: Outcomes of Philadelphia Positive Acute Lymphoblastic Leukemia in Adolescent and Young Adults. (Pubmed Central) - Jan 17, 2023
TKI availability remains a significant issue in low-income countries due to significant financial burden on the patients. Allo-SCT continues to be an attractive option, particularly in low-income countries providing an option for cure in Ph+ ALL.
- || fluocinolone acetonide / Generic mfg.
Review, Journal: Corticosteroid implants for chronic non-infectious uveitis. (Pubmed Central) - Jan 17, 2023
We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register), MEDLINE Ovid, Embase, PubMed, LILACS, and three trials registries to November 2021. SELECTION CRITERIA: We included randomized controlled trials comparing either fluocinolone acetonide (FA) or dexamethasone (DEX) intravitreal implants with standard-of-care therapy or sham procedures, with at least six months of follow-up after treatment...Nevertheless, the evidence suggests that these implants may increase the risk of cataract progression and IOP elevation, which will require interventions over time. To better understand the efficacy and safety profiles of corticosteroid implants, we need future trials that examine implants of different doses, used for different durations. The trials should measure core standard outcomes that are universally defined, and measured at comparable follow-up time points.
- | selonsertib (GS-4997) / Gilead
Journal: Apigenin ameliorates non-eosinophilic inflammation, dysregulated immune homeostasis and mitochondria-mediated airway epithelial cell apoptosis in chronic obese asthma via the ROS-ASK1-MAPK pathway. (Pubmed Central) - Jan 17, 2023
This study demonstrates for the first time the therapeutic effect of apigenin in chronic obese asthma and further clarifies its potential therapeutic targets. In addition, this study clarifies the specificity of chronic obese asthma and provides new options for its treatment.
- | Polivy (polatuzumab vedotin-piiq) / Roche
Trial initiation date: Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Jan 17, 2023
P2, N=44, Not yet recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
In addition, this study clarifies the specificity of chronic obese asthma and provides new options for its treatment. Initiation date: Dec 2022 --> May 2023
- | Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis (clinicaltrials.gov) - Jan 17, 2023
P1/2, N=45, Recruiting, Sponsor: National Human Genome Research Institute (NHGRI)
Initiation date: Dec 2022 --> May 2023 Trial completion date: Dec 2027 --> Apr 2026 | Trial primary completion date: Dec 2027 --> Apr 2024
- ||||| Ocrevus (ocrelizumab) / Roche, Biogen
Enrollment closed, Head-to-Head: Ocarina II: A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (clinicaltrials.gov) - Jan 17, 2023
P3, N=234, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2027 --> Apr 2026 | Trial primary completion date: Dec 2027 --> Apr 2024 Recruiting --> Active, not recruiting
- ||| azacitidine / Generic mfg.
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, IO biomarker: Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab (clinicaltrials.gov) - Jan 17, 2023
P2, N=5, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=23 --> 5 | Trial completion date: Jun 2023 --> Jan 2024 | Trial primary completion date: Jun 2023 --> Jan 2024
- || budesonide / Generic mfg.
Quickest Research Results possible? Single session nebulized budesonide, mechanical hammer percussion of the ribcage, followed by Barral Visceral Manipulation. (Twitter) - Jan 17, 2023
- ||| dexamethasone / Generic mfg.
Clinical: Otherwise they will perform no better than current large hospital systems Where doctors are constrained by protocol and fail to learn over 2 years: - that Dexamethasone 6mg (capped!) is failing to prevent post-day8 hyperinflammatory phase in many (escalatory is better) (Twitter) - Jan 16, 2023
- ||| dexamethasone / Generic mfg., lenalidomide / Generic mfg., carfilzomib / Generic mfg.
P3 data, P3 data: top line, Journal: Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. (Pubmed Central) - Jan 16, 2023
P3
Recruiting --> Active, not recruiting | N=23 --> 5 | Trial completion date: Jun 2023 --> Jan 2024 | Trial primary completion date: Jun 2023 --> Jan 2024 This interim analysis provides support for considering carfilzomib, lenalidomide, and dexamethasone therapy in patients with newly diagnosed multiple myeloma who completed any induction regimen followed by autologous stem-cell transplantation, which requires confirmation after longer follow-up of this ongoing phase 3 trial.
- | dexamethasone / Generic mfg., lenalidomide / Generic mfg., carfilzomib / Generic mfg.
Journal: Carfilzomib, lenalidomide, and dexamethasone maintenance for multiple myeloma: when and for whom? (Pubmed Central) - Jan 16, 2023
This interim analysis provides support for considering carfilzomib, lenalidomide, and dexamethasone therapy in patients with newly diagnosed multiple myeloma who completed any induction regimen followed by autologous stem-cell transplantation, which requires confirmation after longer follow-up of this ongoing phase 3 trial. No abstract available
- | dexamethasone / Generic mfg.
Journal: The association between bronchopulmonary dysplasia grade and risks of adverse neurodevelopmental outcomes among preterm infants born at less than 30 weeks of gestation. (Pubmed Central) - Jan 16, 2023
Small for gestational age, late pulmonary hypertension, dexamethasone administration, and adverse neurodevelopmental outcomes were more common as BPD grade increased...Grades 2 and 3 BPD, but not Grade 1, correlate with risks of adverse neurodevelopmental outcomes at a grade-dependent manner in our single-center cohort retrospective study. Further validation using a multi-center large cohort is warranted.
- || Even with high CRP treatment with Colchicine+ IVM + Clopidogrel+ Dexamethasone+ Diclofenac+ Cetrizine+ Famotidine for 15 to 30 days seems to gradually bring down the CRP number back to normal limits within 7-21 days (Twitter) - Jan 15, 2023
- | hydrocortisone / Generic mfg.
Preclinical, Journal: Efficacy of suspended moxibustion stimulating Shenshu (BL23) and Guanyuan (CV4) on the amygdala-HPA axis in rats with kidney-deficiency symptom pattern induced by hydrocortisone. (Pubmed Central) - Jan 15, 2023
Suspended moxibustion can effectively improve the serum levels of ACTH, CRH, and CORT and can up-regulate the mRNA and protein expressions of MR, GR, 11β-HSD1, CRH, and ACTH in the amygdala and hypothalamus of KYDS rats. This may be one of the molecular mechanisms with which moxibustion alleviates KYDS.
- | dexamethasone / Generic mfg.
Journal: Magnetic liposome as a dual-targeting delivery system for idiopathic pulmonary fibrosis treatment. (Pubmed Central) - Jan 15, 2023
Further investigation demonstrated that the expression of α-SMA and collagen deposition was reduced. Altogether, this dual-targeting delivery system can effectively deliver Dex into M2 macrophages in the lung, making it a novel and promising therapeutic system for the IPF treatment.
- | dexamethasone / Generic mfg., indomethacin / Generic mfg.
Journal: Protective effect of soloxolone derivatives in carrageenan- and LPS-driven acute inflammation: Pharmacological profiling and their effects on key inflammation-related processes. (Pubmed Central) - Jan 15, 2023
Moreover, SM was found to prevent inflammation-associated apoptosis of A549 pneumocytes and effectively inhibited the protease activity of thrombin (IC = 10.3 µM) tightly associated with rodent inflammatome. Taken together, our findings demonstrate that soloxolone derivatives can be considered as novel promising anti-inflammatory drug candidates with multi-targeted mechanism of action.
- || dexamethasone / Generic mfg.
Clinical, Journal: Ultrasound-guided pulsed radiofrequency of cervical nerve root for cervical radicular pain: A prospective randomized controlled trial. (Pubmed Central) - Jan 15, 2023
Ultrasound-guided periradicular cervical nerve root PRF exhibited a neuromodulatory effect and was considered effective for patients with cervical radicular pain. It provided a longer duration of pain relief and improvement of neck function for up to 6 months.
- | Journal: A simplified and defined serum-free medium for cultivating fat across species. (Pubmed Central) - Jan 14, 2023
The traditional adipogenic cocktail containing IBMX, dexamethasone, insulin and rosiglitazone is not food-compatible...Two glucocorticoid receptor activators, progesterone and hydrocortisone, found in DMAD and FBS, affect differentiation homogeneity, without playing an essential role in activating adipogenic genes...This was demonstrated in both media types and in four species: ruminant and monogastric. We therefore propose a simplified one-step adipogenic protocol which, given the replacement of rosiglitazone by a food-compatible PPARγ agonist, is suitable for making cultivated fat.
- || prednisolone / Generic mfg.
P2 data, Journal: A Phase II randomised controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS). (Pubmed Central) - Jan 14, 2023
P2
PRedSS was terminated early primarily due to the Covid-19 pandemic, and so was underpowered. Therefore, interpretation must be cautious and results considered inconclusive, indicating the need for a further randomised trial.